...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage
【24h】

Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage

机译:HIV-1 Vif突变体对APOBEC3G / F的不完全中和促进了从CCR5到CXCR4使用的遗传进化

获取原文
获取原文并翻译 | 示例
           

摘要

Incomplete APOBEC3G/F neutralization by a defective HIV-1Vif protein can promote genetic diversification by inducing G-to-A mutations in the HIV-1 genome. The HIV-1 Env V3 loop, critical for coreceptor usage, contains several putative APOBEC3G/F target sites. Here, we determined if APOBEC3G/F, in the presence of Vif-defective HIV-1 virus, can induce G-to-A mutations at V3 positions critical to modulation of CXCR4 usage. Peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM) from 2 HIV-1-negative donors were infected with CCR5-using 81.A-Vif(WT) virus (i.e., with wildtype [WT] Vif protein), 81.A-Vif(E4SG), or 81.A-Vif(K22E) (known to incompletely/partially neutralize APOBEC3G/F). The rate of G-toA mutations was zero or extremely low in 81.A-Vif(WT) and 81.A-Vif(E45G) -infected PBMC from both donors. Conversely, G-to-A enrichment was detected in 81.A-Vif(K22E)-infected PBMC (prevalence ranging from 2.18% at 7 days postinfection [dpi] to 3.07% at 21 dpi in donor 1 and from 10.49% at 7 dpi to 8.69% at 21 dpi in donor 2). A similar scenario was found in MDM. G-to-A mutations occurred at 8 V3 positions, resulting in nonsynonymous amino acid substitutions. Of them, G24E and E25K strongly correlated with phenotypically/genotypically defined CXCR4-using viruses (P = 0.04 and 5.5e-7, respectively) and increased the CXCR4 N-terminal binding affinity for V3 (WT, -40.1 kcal/mol; G24E, -510 kcal/mol; E25K, -522 kcal/mol). The analysis of paired V3 and Vif DNA sequences from 84 HIV-1-infected patients showed that the presence of a Vif-defective virus correlated with CXCR4 usage in proviral DNA (P = 0.04). In conclusion, incomplete APOBEC3G/F neutralization by a single Vif amino acid substitution seeds a CXCR4-using proviral reservoir. This can have implications for the success of CCR5 antagonist-based therapy, as well as for the risk of disease progression.
机译:有缺陷的HIV-1Vif蛋白对APOBEC3G / F的中和作用不完全,可以通过在HIV-1基因组中诱导G-to-A突变来促进遗传多样化。 HIV-1 Env V3回路对于使用共受体至关重要,它包含几个假定的APOBEC3G / F目标位点。在这里,我们确定在存在Vif缺陷的HIV-1病毒的情况下,APOBEC3G / F是否可以在对CXCR4使用的调节至关重要的V3位置诱导G-to-A突变。使用81.A-Vif(WT)病毒(即野生型[WT] Vif蛋白),用CCR5感染来自2个HIV-1阴性供体的外周血单核细胞(PBMC)和单核细胞衍生的巨噬细胞(MDM), 81.A-Vif(E4SG)或81.A-Vif(K22E)(已知不完全/部分中和APOBEC3G / F)。来自两个供体的81.A-Vif(WT)和81.A-Vif(E45G)感染的PBMC中G-toA突变的发生率为零或极低。相反,在81.A-Vif(K22E)感染的PBMC中检测到G-to-A富集(供体1的感染率在感染后7天[dpi]时为2.18%,在21 dpi时为3.07%,在7时为10.49%)供体2在21 dpi时dpi达到8.69%)。在MDM中发现了类似的情况。 G到A突变发生在8个V3位置,导致非同义氨基酸取代。其中,G24E和E25K与使用表型/基因型定义的CXCR4病毒密切相关(分别为P = 0.04和5.5e-7),并增加了CXCR4对V3的N末端结合亲和力(WT,-40.1 kcal / mol; G24E ,-510 kcal / mol; E25K,-522 kcal / mol)。对来自84位HIV-1感染患者的V3和Vif DNA配对序列的分析表明,存在Vif缺陷的病毒与原病毒DNA中CXCR4的使用相关(P = 0.04)。总之,通过单个Vif氨基酸取代进行的不完全APOBEC3G / F中和为使用前病毒库的CXCR4注入了种子。这可能对基于CCR5拮抗剂的疗法的成功以及疾病进展的风险具有影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号